Tonix Gets 1st Pay from Broad-Spectrum Antivirals with Defense Threat Reduction Agency

 Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, received its first payment from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense (DoD), to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. The previously announced award from DTRA is for up to $34 million over five years.

https://www.globenewswire.com/news-release/2024/10/17/2964812/28908/en/Tonix-Pharmaceuticals-Receives-First-Contract-Payment-from-U-S-Department-of-Defense-for-Accelerated-Development-of-Broad-Spectrum-Antivirals-with-the-Defense-Threat-Reduction-Agen.html